Dear Sir/Madam,

Considering the fact that after adoption of the new law “On medicines”  “the registration will be suspended, if marketing authorization holder does not inform about new data on product’s quality, safety and efficacy or does not implement appropriate variation in the registration dossier”, it is advisable to review the registration documents by making the appropriate changes and additions based on updated data.

Download this file (0101176816-eng.PDF)Download[0101176816/27.04.2016]